The biotech firm received manageable observations from a routine FDA inspection but remains on track for BLA resubmissions in Q2 2026.
Alvotech (NASDAQ:ALVO) disclosed the FDA issued a Form 483 following a routine inspection of its Reykjavik manufacturing facility on May 8, 2026. The company stated the observations are addressable and do not reflect broader compliance or operational issues at the site.
Management emphasized the inspection validated recent improvements to current good manufacturing practices (cGMP) and reaffirmed plans to resubmit biologics license applications (BLAs) in Q2 2026. Alvotech maintains its timeline for securing FDA approval within 2026, focusing on finalizing data for upcoming submissions.
The firm develops biosimilar medicines across Europe, North America, and Asia, positioning itself as a key player in the biosimilars market.